bioRxivMicrobiologyPreprint
Evaluation of antibiotic and peptide vaccine strategies for mirror bacterial infections
Abstract
Recent advances in synthetic biology have raised concerns that the creation of bacteria composed completely of mirror-image biomolecules may be possible in the coming decades. Such "mirror bacteria" could pose an unprecedented biosecurity risk, as they are predicted to be highly virulent pathogens resulting from severe immune evasion. Pharmaceutical interventions, including antibiotics and vaccines, could likely provide some limited protection in the event of a mirror bacterial outbreak. Understanding the feasibility of specific pharmaceutical antimirror strategies may help inform the appropriate measures to confront the risks of mirror bacteria. Here, we experimentally evaluated the prospects of previously proposed antimirror antibiotic and vaccine strategies. First, we assessed the expected efficacy of existing antibiotics chloramphenicol, linezolid, tedizolid, and aztreonam against mirror bacteria by characterizing the antibacterial activities of their enantiomers against natural-chirality bacteria. We found that ent-chloramphenicol, ent-linezolid, ent-tedizolid, and ent-aztreonam exhibited minimal antibiotic activity, suggesting that their parent antibiotics would be ineffective against mirror bacterial infections. Second, to explore whether the enantiomers of existing antibiotics could be suitable as antimirror antibiotics, we evaluated the acute toxicities of ent-chloramphenicol, ent-linezolid, ent-tedizolid, and ent-aztreonam in mice, finding that these compounds have favorable acute toxicity profiles compatible with their continued development. Finally, we investigated D-peptide-based approaches to antimirror vaccines, finding that three bacterially-derived D-peptides induced robust D-peptide-specific antibody responses in mice when conjugated to a carrier protein and adjuvanted. Our results support previous suggestions that the enantiomers of existing antibiotics and D-peptide conjugate vaccines represent feasible pharmaceutical strategies against mirror bacterial infections. IMPORTANCETechnologies enabling the creation of mirror bacteria--bacteria constructed of molecules that are mirror images of those found in nature--may be on the horizon. If created, mirror bacteria would likely pose an unprecedented risk to life on earth given their evasion of natural immune responses. Although they would not protect against widespread environmental damage, antibiotics and vaccines could provide some limited protection to human populations in the event of a mirror bacterial outbreak. We experimentally assessed the prospects of three antimirror strategies: repurposing existing antibiotics, developing mirror versions of existing antibiotics, and developing vaccines based on mirror-image peptides. We broadly conclude that many existing antibiotics are unlikely to be effective against mirror bacteria, while the mirror images of existing antibiotics and mirror-image peptides could serve as foundations for antimirror antibiotics and vaccines, respectively. Our findings may help inform discussions on the proper role of medical countermeasures to defend against mirror bacteria.
- organism: mouse
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular dynamics simulations demonstrate reduced antibiotic affinity to mirror bacterial targets
Paul-Enguerrand Fady, Jonah Ciccone·Computational and Structural Biotechnology JournalPeer-reviewed·Mar 1, 2026
- Antibody-recruiting molecules based on mimotope fusion peptides and a dimeric antibiotic
Franz G. Zingl, Meilee L Mekalanos, … John J. Mekalanos·bioRxiv·Sep 30, 2026
- The role of secondary structures of peptide polymers on antimicrobial efficacy and antibiotic potentiation
Swagatam Barman, Alimi Abiodun, … Chuanbing Tang·bioRxiv·Nov 19, 2024
- The antimicrobial peptide DGL13K is active against resistant gram-negative bacteria and subinhibitory concentrations stimulate bacterial growth without causing resistance
S.-U. Gorr, H. V. Brigman, … E. B. Hirsch·bioRxiv·May 8, 2020
- Development of a novel glycoengineering platform for the rapid production of conjugate vaccines.
S. Abouelhadid, E. Atkins, … J. Cuccui·bioRxiv·Nov 25, 2021
- Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: a new approach to prevent and treat bacterial infections
K. Johnson, J. Delaney, … D. Skurnik·bioRxiv·Dec 28, 2022